Werewolf Therapeutics (HOWL) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Werewolf Therapeutics (HOWL) over the past year, losing 50.1% versus a loss of 51.6%. Werewolf Therapeutics is the larger company by market cap ($44.2 million vs $42.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | NSRX |
|---|---|---|
| Share price | $0.91 | $3.63 |
| Market cap | $44.23M | $42.52M |
| 1-day change | -1.10% | -3.84% |
| YTD return | +43.53% | -60.33% |
| 1-year return | -51.60% | -50.07% |
| 5-year return | -94.67% | — |
| EPS (TTM) | $-0.73 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.94 | $9.50 |
| 52-week low | $0.27 | $1.98 |
| Distance from 52-week high | -53.02% | -61.79% |
| Analyst consensus | none | buy |
| Avg. price target upside | +669.23% | +441.87% |
| Average volume | 6.80M | 16.09K |
| Shares outstanding | 48.60M | 11.71M |
| Employees | 39 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
HOWL vs NSRX FAQ
Which is bigger, Werewolf Therapeutics or Nasus Pharma?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $44.23M compared with $42.52M for Nasus Pharma (NSRX).
Which stock has performed better over the past year, HOWL or NSRX?
NSRX returned -50.07% over the past 12 months, compared with -51.60% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Nasus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.